HRMY · Harmony Biosciences Holdings, I
$41.52
+1.02% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$2B
Trailing P/E
13.5
Forward P/E
6.2
Dividend yield
—
Beta
0.92
Avg volume
1M
Employees
0K
Daily Change %
1.02%
5 Days Change
-1.49%
10 Days Change
5.69%
30 Days Change
5.31%
60 Days Change
12.98%
Month to Day Change
0.90%
Year to Day Change
11.22%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — HRMY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-26
Latest call per bank · past 12 months
Deutsche Bank
Hold$36.00
-12.4% vs priceUBS
Neutral$36.00
-12.4% vs priceBank of America
Underperform$28.00
-31.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-26 | Wolfe Research | Initiates | Outperform | $0.00 → $60.00 |
| 2026-08-05 | Truist Securities | Maintains | Hold | $29.00 → $34.00 |
| 2026-08-04 | Needham | Maintains | Buy | $45.00 → $50.00 |
| 2026-07-31 | Mizuho | Maintains | Outperform | $50.00 → $51.00 |
| 2026-07-16 | HC Wainwright & Co. | Reiterates | Buy | $55.00 |
| 2026-06-30 | Deutsche Bank | Maintains | Hold | $30.00 → $36.00 |
| 2026-05-08 | Truist Securities | Maintains | Hold | $25.00 → $29.00 |
| 2026-02-25 | UBS | Maintains | Neutral | $46.00 → $36.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 60 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.2% above the 50-day MA ($38.02).
- Price vs 200-day MA: Trading 20.7% above the 200-day MA ($34.39).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.02) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($42.86).
HRMY Price Chart
Loading chart for HRMY…
Fundamentals
About Harmony Biosciences Holdings, I
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.